Meet
Sarah Moselle

Principal

Sarah Moselle supports clients with strategy development and implementation across a range of health policy and market access issues in US and international contexts.

She applies her background in public health and global vaccine delivery to create strategic and tactical recommendations for biopharmaceutical clients.

Prior to joining Avalere, Sarah held several research and implementation roles, including most recently as a program manager with the Sabin Vaccine Institute. She previously worked on a variety of health systems strengthening and preventive health service initiatives with the Aga Khan Foundation in Central Asia and with IQVIA Asia Pacific’s public health team.

Sarah has an MA from Wilfrid Laurier University, an MPH with a concentration in health policy and management from the Harvard School of Public Health, and a graduate certificate in Health Economics and Outcomes Research from Tufts University's Center for the Evaluation of Value and Risk in Health.

Authored Content

January 28, 2025 | Insights & Analysis > Federal and State Policy

Vaccine Policy and Access Under New HHS Leadership
Policy actions in the first days of the Trump administration raise questions about the future role of key vaccine advisory committees.
April 17, 2024 | Insights & Analysis > Vaccines and Public Health

Key Policy and Access Themes from the World Vaccines Congress
The World Vaccine Congress addressed the changing landscape of infectious diseases and vaccine types, approvals, recommendations, and reimbursement pathways.
December 19, 2023 | Insights & Analysis > RWE and Patient-Centered Outcomes

2023 Top Trends in HEOR: Policy’s Pressure on HEOR
Avalere experts dive into Trend #9: Policy’s Pressure on HEOR and explore implications of recent policy developments on evidence strategies.
December 15, 2023 | Videos > RWE and Patient-Centered Outcomes

Video: Policy’s Pressure on HEOR
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #9: Policy’s Pressure on HEOR.
November 2, 2023 | Insights & Analysis > Quality Improvement

State of the GRACE Framework: ICER Pilots for HTAs
ICER recently proposed piloting the GRACE framework in place of traditional cost-effectiveness analysis. We review the background of GRACE and its implications.
October 10, 2023 | Insights & Analysis > Vaccines and Public Health

Influenza B Strain Removal Could Impact Future Flu Vaccines
WHO and VRBPAC recommendations to move back toward trivalent influenza vaccines may cause significant shifts in the global flu vaccine landscape.
October 3, 2023 | Insights & Analysis > Digital Health

Third Party to Assess Value of Digital Health Technology
As the US value assessment landscape evolves, a new third-party framework may standardize requirements and open reimbursement pathways for digital health.
August 7, 2023 | Insights & Analysis > Vaccines and Public Health

Therapeutic Vaccines Raise Regulatory, Policy Pathway Questions
In light of the growing therapeutic vaccine pipeline, policymakers are starting to define coverage, access, and reimbursement pathways.
July 25, 2023 | Insights & Analysis > RWE and Patient-Centered Outcomes

Use of Patient-Centered Outcomes in ICER Assessments
Avalere assessed the current use of patient-centered outcomes in ICER evidence reports and determined the patient voice minimally influences modeling results.
June 15, 2023 | Insights & Analysis > Value-Based Care

ICER Opens Brief Comment Period on Proposed Framework Updates
ICER announced proposed changes to its Value Assessment Framework. Stakeholders have limited time to review and comment by June 30.
May 26, 2023 | Insights & Analysis > Vaccines and Public Health

MDRP Proposal Will Impact Vaccine and Novel Immunization Landscape
The proposed vaccine definition would have a significant market impact on novel immunizations such as preventive immunoglobulins and therapeutic vaccines.
November 10, 2022 | Interviews > Vaccines and Public Health

Podcast: RSV Prevention, Part IV: Immunocompromised Populations
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
November 3, 2022 | Videos > Vaccines and Public Health

Video: RSV Prevention, Part IV: Immunocompromised Populations
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
October 10, 2022 | Insights & Analysis > Drug Pricing and Affordability

Inflation Reduction Act Renews Focus on Value Assessment in the US
Government price-setting provisions in the IRA have highlighted the diverse nature and interpretation of value across the US healthcare system.
September 28, 2022 | Videos > Vaccines and Public Health

Video: RSV Prevention, Part I: Pediatric Monoclonal Antibodies
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
June 13, 2022 | Insights & Analysis > Regulatory Strategy and FDA Policy

Global Regulatory Agilities During the COVID-19 Pandemic
Avalere reviewed innovative regulatory approaches deployed during the pandemic, their impact on a diverse set of stakeholders, and how they could be sustained.
April 28, 2022 | Insights & Analysis > Regulatory Strategy and FDA Policy

Ex-US Approaches to Drug Accelerated Approval
International methods of expedited approval offer approaches that policymakers may adopt to reform the US system, as signaled in recent legislative proposals.